|

mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults

RECRUITINGPhase 1Sponsored by Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Actively Recruiting
PhasePhase 1
SponsorVaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Started2026-11-16
Est. completion2028-02-29
Eligibility
Age18 Years – 25 Years
Healthy vol.Accepted

Summary

This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.

Eligibility

Age: 18 Years – 25 YearsHealthy volunteers accepted
Inclusion Criteria:

* Aged 18 to 25 years, inclusive
* Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment

Exclusion Criteria:

* Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation
* Likely or confirmed myocarditis or pericarditis
* Prior receipt of an investigational EBV vaccine
* Prior receipt of a licensed vaccine within 56 days prior to Day 1
* Received more than 10 days of any systemic immunosuppressants or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study.
* For participants of childbearing potential: pregnant, breastfeeding or planning to become pregnant during the study

Note: Other inclusion and exclusion criteria apply.

Conditions2

CancerEBV

Interventions1

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.